Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 3

Фенотипы хронической обструктивной болезни легких – путь к персонифицированной терапии
Н.В. Трушенко, М.И. Сопова, В.И. Сопова

References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2019. Available from: https://goldcopd.org/gold-reports/ Accessed 2019 Dec 12.
2. Fragoso E, André S, Boleo-Tomé JP, Areias V, Munhá J, Cardoso J; GI COPD-Interest Group on Chronic Obstructive Pulmonary Disease. Understanding COPD: a vision on phenotypes, comorbidities and treatment approach. Revista Portuguesa de Pneumologia 2016 Jan;22(2):101-11.
3. Jameson JL, Longo DL. Precision medicine – personalized, problematic, and promising. The New England Journal of Medicine 2015 Jun;372(23):2229-34.
4. Vázquez JH, García IA, Jiménez-garcía R, Álvaro Meca A, de Andrés AL, Ruiz CM, Buendía García MJ, de Miguel Díez J. COPD phenotypes: differences in survival. International Journal of COPD 2018;13:2245-51.
5. Miravitlles M, Soler-Cataluña JJ, Calle Rubio M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera Salmeron P, Simón A, López-Campos JL, Soriano JB, Ancochea J. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Atencion Primaria 2012 Jul;44(7):425-37.
6. Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, Sedlak V, Kocianova J, Zatloukal J, Hejduk K, Pracharova S; Czech Pneumological and Phthisiological Society. Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic 2013 Jun;157(2):189-201.
7. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology 2006 Nov;11(6):731-40.
8. Petrakovskaia V, Belevskiy A, Avdeev S, Blong K. Phenotypes in patients with severe and very severe COPD in the Russian Federation: observational multicenter non-interventional study CLOUD. The American Thoracic Society International Congress, 18-23 May 2018; San Diego, USA.
9. Arkhipov VV, Arkhipova DE, Stukalina EYu, Lazarev AA. COPD phenotypes in Russia: characteristics and treatment. Practical Pulmonology 2016;3:20-5 (In Russian).
10. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004 Jul;126(1):59-65.
11. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003 Apr;58(4):322-7.
12. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. The Lancet. Respiratory Medicine 2015 Jun;3(6):435-42.
13. Kang HS, Rhee CK, Kim SK, Kim JW, Lee SH, Yoon HK, Ahn JH, Kim YH. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD. Internal Journal of Chronic Obstructive Pulmonary Disease 2016 Oct;11:2467-73.
14. Prins HJ, Duijkers R, Lutter R, Daniels JM, van der Valk P, Schoorl M, Kerstjens HA, van der Werf TS, Boersma WG. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respiratory Medicine 2017 Oct;131:118-24.
15. Zanini A, Cherubino F, Zampogna E, Croce E, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:1155-61.
16. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf Accessed 2019 Dec 12.
17. Soler-Cataluña JJ, Cosío B, Izquierdo JL, López-Campos JL, Marín JM, Agüero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, González MC, Miravitlles M, Monsó E, Montemayor T, Morera J, Ortega F, Peces-Barba G, Puente L, Rodríguez JM, Sala E, Sauleda J, Soriano JB, Viejo JL. Consensus document on the overlap phenotype COPD-asthma in COPD. Archivos de Bronconeumologia 2012 Sep;48(9):331-7.
18. Lopez-Campos JL, Centanni S. Current approaches for phenotyping as a target for precision medicine in COPD management. COPD 2018 Apr;15(2):108-17.
19. Hardin M, Silverman EK, Barr RG, Hansel N, Schroeder JD, Make M, Crapo JD, Hersh CP; COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respiratory Research 2011;12:127.
20. Miravitlles M, Soriano JB, Ancochea J, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, García-Río F. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respiratory Medicine 2013 Jul;107(7):1053-60.
21. Menezes AMB, Montes de Oca M, Pérez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, Muiño A, Jardim JRB, Valdivia G, Tálamo C; PLATINO Team. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014 Feb;145(2):297-304.
22. Averyanov AV, Polivanov GE. Emphysema. Practical Pulmonology 2006;(4):2-7 (In Russian).
23. Martini K, Frauenfelder T. Emphysema and lung volume reduction: the role of radiology. Journal of Thoracic Disease 2018 Aug;10(Suppl 23):S2719-31.
24. Devasahayam J, LaFreniere K, Naik R. Chronic emphysema. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2019 Jul 16.
25. Soffler MI, Hayes MM, Schwartzstein RM. Respiratory sensations in dynamic hyperinflation: physiological and clinical applications. Respiratory Care 2017 Sep;62(9):1212-23.
26. Verbanck S, Schuermans D, Vincken W. Small airways ventilation heterogeneity and hyperinflation in COPD: Response to tiotropium bromide. International Journal of Chronic Obstructive Pulmonary Disease 2007 Dec;2(4):625-34.
27. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine 2011 Apr;105(4):580-7.
28. D’Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Research 2011 Dec;12:156.
29. O’Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respiratory Medicine 2011 Jul;105(7):1030-6.
30. Avdeyev SN, Trushenko NV. Effects of fixed combination of indacaterol/glycopyrronium in chronic obstructive pulmonary disease: state-of-the art review. Russian Pulmonology 2018;28(2):224-33 (In Russian).
31. Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics 2015 Jun;32:53-9.
32. Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. The Lancet. Respiratory Medicine 2018 May;6(5):368-78.
33. DeCamp MM Jr, Lipson D, Krasna M, Minai OA, McKenna RJ Jr, Thomashow BM. The evaluation and preparation of the patient for lung volume reduction surgery. Proceedings of the American Thoracic Society 2008 May;5(4):427-31.
34. Washko GR, Fan VS, Ramsey SD, Mohsenifar Z, Martinez F, Make BJ, Sciurba FC, Criner GJ, Minai O, Decamp MM, Reilly JJ; National Emphysema Treatment Trial Research Group.The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine 2008;177(2):164-9.
35. Wilkens H, Demertzis S, König J, Leitnaker CK, Schäfers HJ, Sybrecht GW. Lung volume reduction surgery versus conservative treatment in severe emphysema. The European Respiratory Journal 2000 Dec;16(6):1043-9.
36. Sanchez PG, Kucharczuk JC, Su S, Kaiser LR, Cooper JD. National Emphysema Treatment Trial redux: accentuating the positive. The Journal of Thoracic and Cardiovascular Surgery 2010 Sep;140(3):564-72.
37. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, Fishman AP; National Emphysema Treatment Trial Research Group. Long-term follow‐up of patients receiving lung‐volume‐reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. The Annals of Thoracic Surgery 2006 Aug;82(2):385-7.
38. Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hübner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH; TRANSFORM Study Team. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). American Journal of Respiratory and Critical Care Medicine 2017 Dec;196(12):1535-43.
39. Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. Journal of the European Academy of Dermatology and Venereology 2018;32(3):397-402.
40. Sciurba FC, Criner GJ, Strange Ch, Shah PL, Michaud G, Connolly TA, Deslée G, Tillis WP, Delage A, Marquette ChH, Krishna G, Kalhan R, Ferguson JS, Jantz M, Maldonado F, McKenna R, Majid A, Rai N, Gay S, Dransfield MT, Angel L, Maxfield R, Herth FJF, Wahidi MM, Mehta A, Slebos DJ; for the RENEW Study Research Group. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW randomized clinical trial. JAMA 2016 May;315(20):2178-89.
41. Deslée G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Thiberville L, Leroy S, Marceau A, Laroumagne S, Mallet JP, Dukic S, Barbe C, Bulsei J, Jolly D, Durand-Zaleski I, Marquette CH; REVOLENS Study Group. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: The REVOLENS Randomized Clinical Trial. Journal of the American Medical Association 2016 Jan;315(2):175-84.
42. Herth FJF, Shah P, Valipour A, Eberhardt R, Grah C, Egan J, Ficker J, Wagner M, Witt C, Liebers U, Gesierich W, Stanzel F, Phillip M, McNulty W, Hopkins P, Petermann C, Snell G, Gompelmann D. STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results. The European Respiratory Journal 2016 Sep;48(Suppl 60):OA475.
43. Quint JK, Millett ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004-2013: a population based cohort study. The European Respiratory Journal 2016 Jan;47(1):186-93.
44. Arram EO, Elrakhawy MM. Bronchiectasis in COPD patients. The Egyptian Journal of Chest Diseases & Tuberculosis 2012 Oct;61(4):307-12.
45. Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, Perpiñá-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140(5):1130-7.
46. Minov J, Stoleski S, Mijakoski D, Vasilevska K, Atanasovska A. Exacerbations in COPD Patients with Bronchiectasis. Medical Sciences (Basel) 2017;5(2):7.
47. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010 Jul;65(Suppl 1):i1-58.
48. Kim V, Criner GJ. The chronic bronchitis phenotype in COPD: features and implications. Current Opinion in Pulmonary Medicine 2015 Mar;21(2):133-41.
49. Kardos P, Mokros I, Sauer R, Vogelmeier CF. Health status in patients with COPD treated with roflumilast two large non interventional real-life studies: DINO and DACOTA. International Journal of Chronic Obstructive Lung Disease 2018 May;13:1455-68.
50. Yuan L, Dai X, Yang M, Cai Q, Shao N. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Lung Disease 2016 Jun;11:1477-83.
51. Cilli A, Bal H, Gunen H. Efficacy and safety profile of roflumilast in a real-world experience. Journal of Thoracic Disease 2019 Apr;11(4);1100-5.
52. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review 2015 Sep;24(137):451-61.
53. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 2017 Oct;14(5):552-63.
54. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. The Cochrane Database of Systematic Review 2019 May 20;5:CD001287.
55. Avdeyev SN, Trushenko NV, Merzhoeva ZM, Ivanova MS, Kusrayeva EV. Eosinophilic inflammation in chronic obstructive pulmonary disease. Therapeutic Archive 2019;91(10):144-52 (In Russian).
56. DiSantostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respiratory Medicine 2016 Mar;112:88-96.
57. Hasegawa K, Camargo CA Jr. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology 2016 May;21(4):761-4.
58. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R; ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. The European Respiratory Journal 2014 Dec;44(6):1697-700.
59. Cheng SL, Lin CH. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. International Journal of Chronic Obstructive Lung Disease 2016 Sep;11:2341-8.
60. Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis. NPJ Primary Care Respiratory Medicine 2017;27(1):17.
61. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. The New England Journal of Medicine 2017 Oct;377(17):1613-29.
62. Huang WC, Tsai YH, Wei YF, Kuo PH, Tao CW, Cheng SL, Lee CH, Wu YK, Chen NH, Hsu WH, Hsu JY, Wang CC, Lin MS. Wheezing, a signi cant clinical phenotype of COPD: experience from the Taiwan Obstructive Lung Disease Study. Internatoinal Journal of COPD 2015 Oct;10:2121-6.
63. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000 Sep;118(3):656-64.
64. Tantucci C, Modina D. Lung function decline in COPD. International Journal of Chronic Obstructive Lung Disease 2012;7:95-9.
65. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006 Jun;61(6):472-7.
66. Kesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1– evidence from the UPLIFT trial. Respiratory Research 2011 Sep;12(1):129.
67. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2012 Jan;185(1):44-52.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]